Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

Research To Practice | Oncology Videos · Sep 26, 2025 · 21m

Featuring an interview with Dr Kevin Kalinsky, including the following topics:

Patient-Reported Outcomes from the TROPION-Breast01 Study (0:00)

Pernas S et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes from the TROPION-Breast01 study. ASCO 2024;Abstract 1006.

Indirect Comparison of Sacituzumab Govitecan and Datopotamab Deruxtecan for Advanced Breast Cancer (5:04)

Pathak N et al. Indirect comparison of sacituzumab govitecan (SG) and…